速递｜诺和诺德，将GLP-1新药战线推进至儿童青少年人群

GLP1减重宝典01-20

整理 | GLP1减重宝典内容团队1 月 19 日，国家药品监督管理局药品审评中心信息显示，诺和诺德旗下 CagriSema 注射液新适应症临床获批，用于在低热量饮食和增加体力活动基础上，8 至 18 岁以下儿童及青少年的长期体重管理。这一进展，标志着 GLP-1 类药物竞争正式从成人肥胖，延伸至更具争议、也更具长期价值的青少年人群。从产业逻辑看，这是一次极具战略意味的推进。青少年肥胖不仅是体重...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2604961481?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-20 17:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2604961481","market":"us","top_or_hot":-1,"title":"速递｜诺和诺德，将GLP-1新药战线推进至儿童青少年人群","media":"GLP1减重宝典","content":"<div>\n<p>整理 | GLP1减重宝典内容团队1 月 19 日，国家药品监督管理局药品审评中心信息显示，诺和诺德旗下 CagriSema 注射液新适应症临床获批，用于在低热量饮食和增加体力活动基础上，8 至 18 岁以下儿童及青少年的长期体重管理。这一进展，标志着 GLP-1 类药物竞争正式从成人肥胖，延伸至更具争议、也更具长期价值的青少年人群。从产业逻辑看，这是一次极具战略意味的推进。青少年肥胖不仅是体重...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速递｜诺和诺德，将GLP-1新药战线推进至儿童青少年人群</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速递｜诺和诺德，将GLP-1新药战线推进至儿童青少年人群\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-20 17:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b><strong>GLP1减重宝典</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>整理 | GLP1减重宝典内容团队1 月 19 日，国家药品监督管理局药品审评中心信息显示，诺和诺德旗下 CagriSema 注射液新适应症临床获批，用于在低热量饮食和增加体力活动基础上，8 至 18 岁以下儿童及青少年的长期体重管理。这一进展，标志着 GLP-1 类药物竞争正式从成人肥胖，延伸至更具争议、也更具长期价值的青少年人群。从产业逻辑看，这是一次极具战略意味的推进。青少年肥胖不仅是体重...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4590","symbol_name":"PTP","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b","article_id":"2604961481","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120173543a44073f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604961481","pubTimestamp":1768900241,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"整理 | GLP1减重宝典内容团队1 月 19 日，国家药品监督管理局药品审评中心信息显示，诺和诺德旗下 CagriSema 注射液新适应症临床获批，用于在低热量饮食和增加体力活动基础上，8 至 18 岁以下儿童及青少年的长期体重管理。这一进展，标志着 GLP-1 类药物竞争正式从成人肥胖，延伸至更具争议、也更具长期价值的青少年人群。CagriSema 作为胰淀素类似物与 GLP-1 的复方方案，本身就被视为诺和诺德下一代减重核心资产。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4590":"PTP","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4144":"石油与天然气的储存和运输","BK4599":"减肥药","BK4007":"制药"},"translate_title":"Express | Novo Nordisk, pushing the GLP-1 new drug front line to children and adolescents","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96},"content_text":"整理 | GLP1减重宝典内容团队1 月 19 日，国家药品监督管理局药品审评中心信息显示，诺和诺德旗下 CagriSema 注射液新适应症临床获批，用于在低热量饮食和增加体力活动基础上，8 至 18 岁以下儿童及青少年的长期体重管理。这一进展，标志着 GLP-1 类药物竞争正式从成人肥胖，延伸至更具争议、也更具长期价值的青少年人群。从产业逻辑看，这是一次极具战略意味的推进。青少年肥胖不仅是体重问题，更是未来 2 型糖尿病、心血管疾病和代谢综合征的“起点风险”。一旦在这一人群中建立起长期、规范化的药物干预路径，其临床价值和生命周期远高于短期减重应用。但与此同时，该人群对安全性、耐受性和长期随访数据的要求也显著高于成人，这使得真正敢于推进临床的企业并不多。CagriSema 作为胰淀素类似物与 GLP-1 的复方方案，本身就被视为诺和诺德下一代减重核心资产。此次将适应症指向青少年，意味着诺和诺德并不满足于在“成人减重天花板”内内卷，而是试图提前卡位更长期、更系统的体重管理场景，从源头介入肥胖的自然病程。更值得关注的是，该适应症明确强调“在生活方式干预基础上”，这也为未来监管与支付留下空间。它并非替代饮食与运动，而是作为强化工具嵌入慢病管理体系，这一定位更符合当前全球监管机构对儿童与青少年用药的审慎态度。在 GLP-1 赛道高度拥挤的当下，这一动作释放出一个清晰信号：竞争的核心，正在从成人减重幅度的比拼，转向谁能在更早期人群、更长周期管理中建立临床与制度优势。青少年体重管理，或将成为下一阶段真正拉开差距的新战场。*本文仅供医疗卫生专业人士参考","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604961481","isCrawlerRequest":true}